The George Washington University Hospital announced today that it is one of the first hospitals in Washington, DC to offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. One in two men ages 51 to 60 have BPH, and the incidence increases every decade of life.1 If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones, and incontinence.
The problem with BPH surgical treatments today is that they often force men to trade off between symptom relief and side effects, limiting patients to choose between either a high degree of symptom relief with high rates of irreversible complications (such as incontinence, erectile dysfunction, or ejaculatory dysfunction) or low degree of symptom relief with low rates of irreversible complications. Aquablation therapy is a different type of treatment for BPH. It’s an advanced, minimally invasive treatment that uses the power of water delivered with robotic precision to provide best-in-class and long-lasting symptom relief with low rates of irreversible complications, regardless of prostate size or shape.2,3
Aquablation therapy is performed by the AquaBeam Robotic System, the first FDA-cleared, surgical robot utilizing automated tissue resection for the treatment of LUTS due to BPH. It combines real-time, multi-dimensional imaging, automated robotic technology, and heat-free waterjet ablation technology for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience.
Aquablation therapy has proven results. In clinical studies, Aquablation therapy has shown to provide both best-in-class and durable symptom relief with low rates of irreversible complications.2,3,4
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on BPH, the AquaBeam Robotic System delivering Aquablation therapy is the first FDA-cleared, surgical robot utilizing automated tissue resection for the treatment of lower urinary tract symptoms due to BPH. Aquablation therapy combines real-time, multi-dimensional imaging, automated robotic technology, and heat-free waterjet ablation technology for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience.
1 Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clinical Interventions in Aging 2008:3(3).
2 Gilling, P, et al. Three-Year Outcomes after Aquablation Therapy Compared to TURP: Results from a Blinded Randomized Trial. Can J Urol. 2020 Feb;27(1):10072-10079.
3 Desai, M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Can J Urol. 2020 Apr;27(2):10147-10153.
4 Bach, T, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb; 9(2): 603.
Individual results may vary. There are risks associated with any surgical procedure. Talk with your doctor about these risks to find out if minimally invasive surgery or robotic surgery are right for you.